newsfilter
← Latest News
Business Wire·

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that